Tag: Amgen

European Commission approves Prolia for patients with glucocorticoid-induced osteoporosis

Amgen has announced that the European Commission (EC) has approved a new indication for Prolia (denosumab) for the treatment of bone loss associated with long-term systemic...

Romosozumab leads to significant bone mineral density gains at lumbar spine...

UCB and Amgen have announced results from the Phase 3 BRIDGE study showing that in men with osteoporosis, the investigational agent romosozumab resulted in...